Enhances and speeds up small molecule and biologics discovery research
PRINCETON, N.J.— 2022 年 3 月 8 日 – Certara, Inc., a global leader in biosimulation, today announced the release of D360 Scientific Informatics software version 22.0. This new release of D360 software delivers new capabilities to better understand sequence-activity relationships (SeqAR) and guide molecular design. D360 software is used by more than 6,500 discovery research scientists and five of the top 10 biopharmaceutical companies.
“Our regular cadence of D360 software releases continually advances timelier insights and efficient data workflow for small molecule and biological candidates, informing smarter and faster decisions,” said Leif Pedersen, president of Software at Certara Software. “We are very pleased with our close collaborations with our clients, who provide us with invaluable feedback on how we can meet their growing needs for enterprise-level discovery informatics support across their portfolio.”
D360 provides self-service access to data, integrated scientific analytics and team collaboration allowing users to focus on science and not on software. The new capabilities in the D360 product portfolio include:
- Biologics modalities: Improved ability to represent cyclic peptides and double stranded DNA/RNA and updates to sequence clustering for better understanding of SeqAR
- Small molecule analytics: Automated determination of activity cliffs for rapid examination of chemical structural changes that elicit large changes in a biological response to better guide and improve molecular design.
- Multi-functional molecules: R-Group analysis enhancements for ready understanding of linker and binding domain changes in multi-domain small molecules such as PROTACS.
- Improved system environment monitoring: Streamlined support of D360 deployments by monitoring data sources for potential issues and early notification of apparent problems in connected systems, further reducing maintenance of D360 data delivery.
Learn more about D360 software at https://www.certara.com/data-and-informatics/d360-scientific-informatics-platform/.
Certara accelerates medicines using proprietary biosimulation software, technology and services that transform traditional drug discovery and development. 製薬、教育機関、規制当局のお客様 2,000人以上、6262ヵ国にてサターラの技術やサービスが活用されています。